XTRA:PUM
XTRA:PUMLuxury

PUMA (XTRA:PUM): Revisiting Valuation After a Steep Slide and Recent Share Price Rebound

PUMA (XTRA:PUM) has been grinding through a tough stretch, and the share price reflects it, with the stock down sharply this year even after a recent bounce. That disconnect is where things get interesting. See our latest analysis for PUMA. Despite a punchy 7 day share price return of 27.22 percent and a modest 30 day gain, the stock is still nursing a steep year to date share price loss, and the multi year total shareholder return remains deeply negative, signaling that momentum is only...
XTRA:RHM
XTRA:RHMAerospace & Defense

The Bull Case For Rheinmetall (XTRA:RHM) Could Change Following Record Backlog And NATO-Focused Expansion Plans - Learn Why

Rheinmetall recently reported strong sales growth and a record order backlog of roughly €64.00 billion, supported by new NATO-linked contracts for HERO loitering munitions and large ammunition orders across Europe. By pairing this very large backlog with plans to expand production capacity within NATO countries and refocus on pure-play defence, the company is aiming to convert surging demand into higher margins and stronger cash generation over the coming years. Next, we'll examine how...
XTRA:SAP
XTRA:SAPSoftware

Is SAP Still Attractively Priced After Its Volatile 2025 Share Price Performance?

Wondering if SAP is a bargain or just fairly priced after its big run up over the last few years? This breakdown will help you decide whether the stock still earns a place on your watchlist. Recently, SAP has been choppy, up 1.5% over the last week but down 7.4% over the past month, with the stock now sitting about 12.9% lower year to date and roughly 10.0% off over the last 12 months, while still having more than doubled over 3 and 5 years. These swings have come as investors digest SAP's...
XTRA:M8G
XTRA:M8GMedia

3 European Growth Companies Where Insiders Own At Least 10%

The European stock markets have shown positive momentum, with the pan-European STOXX Europe 600 Index closing 2.35% higher and major single-country indexes also experiencing gains. Amidst this backdrop of market optimism and relatively subdued inflation, growth companies with high insider ownership can be appealing to investors as they often signal strong confidence from those closest to the business.
XTRA:TKA
XTRA:TKAMetals and Mining

Thyssenkrupp (XTRA:TKA): Rethinking Valuation After Sweeping Restructuring Deal With IG Metall

Thyssenkrupp (XTRA:TKA) just signed a sweeping restructuring deal with IG Metall, locking in financing while cutting or outsourcing about 11,000 jobs and trimming steel capacity to roughly 8.7 to 9 million tonnes. See our latest analysis for thyssenkrupp. The restructuring news appears to have supercharged sentiment, with an 8.31% 1 day share price return and a 142.86% year to date share price return. Together, these have contributed to a powerful 246.70% 1 year total shareholder return that...
DB:TNIE
DB:TNIELeisure

European Value Stocks Priced Below Estimated Worth

As European markets experience a positive upturn, with the pan-European STOXX Europe 600 Index closing 2.35% higher and major single-country indexes also on the rise, investors are increasingly turning their attention to value stocks that may be priced below their estimated worth. In such an environment, identifying stocks that are undervalued can offer opportunities for investors seeking to capitalize on potential market inefficiencies and favorable economic conditions.
XTRA:BAYN
XTRA:BAYNPharmaceuticals

Bayer (XTRA:BAYN) Is Up 10.8% After Oncology And Cardio Pipelines Clear Key FDA Hurdles - What's Changed

In recent weeks, Bayer has reported a series of product milestones, including FDA approval of HYRNUO for HER2-mutated non-small cell lung cancer, positive Phase III stroke-prevention data for asundexian, and the launch of the SUNFLOWER Phase III trial assessing Mirena for treating nonatypical endometrial hyperplasia. Alongside expanded FDA-cleared uses for its MEDRAD Centargo CT injector, these updates highlight Bayer’s efforts to broaden its pharmaceuticals and medical imaging franchises...
XTRA:SIE
XTRA:SIEIndustrials

Is Siemens Fairly Priced After Energy Contracts and Recent Share Price Dip?

Curious whether Siemens stock is a bargain right now? Let’s dive in and see how the numbers stack up for investors looking for value. Recently, Siemens shares have experienced a range of movement. The stock has climbed 20.5% year-to-date and 22.6% over the past year. However, it also saw a noticeable dip of 7.2% in the last 30 days. One key reason for these shifts is that Siemens has been in the headlines, with investor sentiment influenced by new contracts in energy infrastructure and...